Veeva Systems (VEEV) Earnings Date & Reports

Key Takeaways

• Veeva Systems (VEEV) reported fiscal 2027 second-quarter revenue of $927.96 million, up 17.6% year over year and above the consensus estimate of roughly $904–905 million.
• Non-GAAP (non-Generally Accepted Accounting Principles) earnings per share came in at $2.35, beating the consensus of $2.22 by about 5.8%.
• Non-GAAP operating income reached approximately $416 million, with a non-GAAP operating margin of 44.8%.
• Management raised its full-year fiscal 2027 outlook, lifting revenue guidance to $3.68–3.69 billion and non-GAAP EPS guidance to roughly $9.21.
• The stock jumped about 8.9% in after-hours trading following the report, reflecting a broadly positive market response.

Earnings Context and Why It Matters

Veeva Systems, a leading provider of cloud software for the life sciences industry, sits at the center of pharmaceutical and biotech digital transformation. Its fiscal 2027 second quarter, which ended July 31, 2026, matters to investors because it offers a snapshot of demand across two key businesses: commercial solutions and research & development (R&D) and quality solutions. The quarter also tested how well Veeva is managing a transition in its R&D portfolio toward newer growth products. With the company's CRM (customer relationship management) franchise facing competitive pressure and its AI initiatives still early stage, this report provided critical evidence of whether Veeva can sustain double-digit growth while expanding profitability.

Reported Results

Veeva delivered total revenue of $927.96 million for the fiscal 2027 second quarter, a 17.6% increase from $789.08 million a year earlier. The result topped Wall Street's consensus estimate of approximately $904–905 million. Subscription revenue rose 16.3% to $766.76 million, while professional services and other revenue climbed 24.1% to $161.2 million.

On the bottom line, non-GAAP net income per share was $2.35, exceeding the $2.22 consensus by roughly 5.8%. GAAP net income was $273.43 million, or $1.68 per basic share and $1.66 per diluted share, up from $1.23 and $1.19, respectively, in the prior-year quarter. Non-GAAP operating income came in near $416 million, ahead of the roughly $395 million analysts expected.

Segment details underscored broad momentum. Veeva Commercial Solutions subscription revenue grew 13% to $347.39 million, while Veeva R&D and Quality Solutions subscription revenue rose 19.3% to $419.38 million. Billings, a closely watched measure of bookings activity, reached $760.9 million, up 17.1% year over year.

Looking ahead, Veeva guided third-quarter revenue to $932–935 million and non-GAAP EPS to $2.33–2.34, both above the respective consensus figures at the time. Full-year fiscal 2027 guidance was raised to revenue of $3.68–3.69 billion and non-GAAP EPS of approximately $9.21.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking earnings-driven movers like VEEV or exploring broader sectors, the AI Screener can help streamline your research process.

Market Reaction and Investor Sentiment

Investors responded enthusiastically to Veeva's fiscal 2027 second-quarter report. The stock rose approximately 8.9% in after-hours trading immediately following the release, climbing toward $266.50 per share. The rally reflected a combination of factors: a revenue beat, an earnings-per-share beat, better-than-expected guidance for both the upcoming quarter and the full fiscal year, and solid billings growth that signaled sustained customer demand.

Sentiment was also supported by commentary around Veeva's commercial cloud, where management cited broad-based momentum across CRM, content, data products, Crossix, and Ostro, and highlighted CRM selections by major biopharma customers. While competitive concerns around CRM remain, the quarter's results and raised guidance appeared to reassure investors that Veeva's growth trajectory remains intact.

Forward Outlook and Key Factors to Monitor

Following this report, investors will be watching whether Veeva can sustain its momentum through the second half of fiscal 2027. Management's raised full-year guidance implies continued double-digit revenue growth and expanding profitability, but execution will depend on several variables.

One area to monitor is the R&D business transition. Veeva is shifting from established products toward newer offerings such as EDC (electronic data capture), eCOA (electronic clinical outcome assessment), RTSM (randomization and trial supply management), Safety, and LIMS (laboratory information management systems). These represent large market opportunities, but they remain relatively early in their adoption cycles.

AI will also be a key theme. Management described Veeva Falcon, its agentic AI initiative, as a new category that could drive future growth, though the company acknowledged it is still the limiting factor as it prepares the product and works with early adopters. Progress on AI monetization and gross margins will be closely scrutinized.

Finally, competitive dynamics in CRM remain a risk. Veeva noted that some large customers chose a competing platform, but believes it may win some of those accounts back in 2027 and 2028. Billings growth, subscription revenue trends, and any changes to full-year guidance in the quarters ahead will offer the clearest signals on whether Veeva's momentum continues.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations